2025 - COVID-19 Vaccine Variant Target: Who Should Choose?
Sensible Medicine
MARCH 12, 2025
As of Aug 30, 2024, the US FDA has granted approval for Comirnaty (Pfizer) and Spikevax (Moderna) and emergency use authorization for Novavax for use in fall 2024 COVID-19 vaccine programs. 1,2 Moderna and Pfizer have manufactured mRNA vaccines targeting the KP.2 SARS-CoV-2 variant, a descendent of the JN.1 strain, whereas the Novavax recombinant protein platform targets the JN.1 variant.
Let's personalize your content